Aviado · Research
Longevity Daily
Wednesday, August 19, 2026
Listen
Today's Brief
Today's digest is threaded by a single insight: what you do in midlife shapes your brain and your lifespan in ways science is now quantifying with precision. Our lead story makes the case — backed by multiple mechanisms — that your cardiovascular health in your 40s and 50s is one of the most powerful predictors of dementia risk. A large Mendelian randomization study adds a provocative twist: in men, higher testosterone correlates with more children and a shorter life. Also in today's issue: a new report asks whether popular senolytic drugs may be harming the very organ they're meant to protect.
10 stories1 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Protect Your Heart in Midlife, Protect Your Brain in Old Age
Your cardiovascular health in midlife is, quite literally, the architecture of your future cognition. A new study reviewed by Fight Aging! confirms multiple overlapping mechanisms: reduced blood flow starves the brain of energy, damaged vessel walls leak inflammatory molecules into brain tissue, and hypertension drives a slow accumulation of small ruptures that silently erode function over decades. The brain's voracious energy demands mean it is one of the first organs to pay the price for circulatory decline. The actionable takeaway is unambiguous — blood pressure control, aerobic fitness, and cardiovascular health in your 40s and 50s are among the most powerful tools available for dementia prevention.
Read more →Are Senolytics Harming Your Brain? New Evidence Raises Concerns
Senolytic drugs — designed to hunt down and clear the zombie cells that accumulate with aging — are a cornerstone of many longevity protocols. But a troubling new report suggests that the brain may actually depend on some senescent cells for normal function, raising the possibility that popular regimens like quercetin-dasatinib combinations could cause unintended neurological damage. If you are cycling senolytics, this is worth reading carefully before your next dose.
Read more →Supplements & Compounds
Daily Resveratrol Reduces TREM2, a Key Target in Alzheimer's and Parkinson's
A new study covered in this week's longevity research roundup found that daily 500mg encapsulated resveratrol supplementation produced a statistically significant reduction in TREM2 — a protein whose dysregulation is implicated in both Alzheimer's and Parkinson's pathology. TREM2 normalization is considered potentially beneficial in neuroinflammatory disease, making this a notable signal for a supplement already widely used by longevity enthusiasts. Sample size details are limited in early coverage; treat this as a promising but preliminary finding.
Read more →Berberine's Research Profile: What the Evidence Actually Shows
Berberine has exploded in popularity as a metabolic health supplement — often dubbed nature's Ozempic — but Nutritional Outlook's rigorous FAQ digs into what the evidence actually supports, alongside real concerns about bioavailability, contamination risk, and quality-control failures that consumers rarely hear about. The piece is aimed at the formulator market but contains frank assessments that any supplement user should know. Essential reading before you add berberine to your stack.
Read more →Research & Papers
Higher Testosterone in Men Linked to More Children — and a Shorter Life
A large Mendelian randomization study (n=184,205 men) found that genetically higher bioavailable testosterone was associated with a 0.74-year shorter lifespan and 0.03 more children per standard deviation increase, after BMI adjustment — a textbook example of antagonistic pleiotropy, where traits that boost reproduction come at a survival cost. Women showed no such association for either outcome. This does not directly indict testosterone therapy, but it adds important nuance to the testosterone optimization conversation and deserves a close read by anyone on TRT.
Read more →Aviado Research: Separating Signal from Noise in Longevity Science
Aviado Research's latest review takes a critical, evidence-based look at the current state of longevity interventions — assessing which approaches have meaningful human data behind them and which remain speculative. This kind of rigorous analysis is precisely what the growing noise in the longevity supplement and therapeutics market demands. Read the full analysis for Aviado's methodology and graded conclusions.
Read the full Aviado analysis →Lifestyle & Nutrition
Your Balance Right Now Is a Window Into Your Longevity
Balance is not just a fitness metric — it is a real-time readout of the integration between your nervous system, musculoskeletal health, and vascular function, all of which decline with age. Fyzical's director of balance education explains how diminished balance initiates a cascade: reduced stability leads to inactivity, falls risk, and metabolic deterioration that compounds over time. Simple assessments — like standing on one leg for 10 seconds — may be more predictive of your longevity trajectory than you would expect from such a low-tech test.
Read more →The Gut-Hormone Connection: How Menopause Reshapes Your Microbiome
Emerging research is illuminating how the gut microbiome shifts significantly during perimenopause — with downstream effects on hormone metabolism, systemic inflammation, and the gut-brain axis. Nutritional Outlook's clinical overview highlights the therapeutic opportunities this creates, from targeted probiotics to dietary strategies that support the estrobolome, the community of gut bacteria that regulate estrogen recycling. For women navigating midlife metabolic changes, the gut microbiome may be among the most underappreciated levers available.
Read more →Industry & Policy
XPRIZE Healthspan Names Finalists in Its Bid to Benchmark Biological Aging
The XPRIZE Healthspan competition has announced its finalist teams, marking a significant milestone in organized, competitive longevity research. Rather than relying on aging clocks alone, the prize structure evaluates interventions against concrete functional benchmarks — including muscle strength, cognitive performance, and immune resilience — in aging adults. Fight Aging! notes the approach represents the kind of rigorous head-to-head comparison the longevity field has long needed but rarely executed.
Read more →Haleon and A*STAR Launch First Clinical Trial of Centrum in Midlife Asian Women
Consumer health giant Haleon and Singapore's A*STAR research institute have launched the ISMOS study — a clinical trial investigating whether Centrum multivitamin supplementation improves metabolic health outcomes in midlife Asian women. The trial targets a significant data gap, as the vast majority of vitamin supplementation research has focused on older Western populations. Results could materially reshape supplementation guidance for a large, historically underrepresented demographic.
Read more →